OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
April 02, 2005
Innovators and generics makers are staking out positions on follow-on proteins and other manufacturing issues.
March 02, 2005
New fixed-dose combination drugs aim to enhance safety and efficacy, while regulators clear a path for more drug–device combination products.
February 02, 2005
Concerns about risky medicines may reduce pressure to expand drug imports while boosting demand for more comparative analyses of therapies.
January 02, 2005
Safety issues and shortages may slow down new drug development and FDA reforms
December 02, 2004
Blockbuster drugs turn out to be risky business, while contamination problems shut down flu vaccine production.
November 02, 2004
Phase II of FDA's GMP modernization plan may involve revising regulations to fit new policies and inspection and review programs.